UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2011
ONYX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE (State of incorporation) |
0-28298 (Commission File No.) |
94-3154463 (IRS Employer Identification No.) |
249 East Grand Avenue
South San Francisco, California 94080
(Address of principal executive offices and zip code)
South San Francisco, California 94080
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (650) 266-0000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 8.01 | OTHER EVENTS |
On July 28, 2011, Bayer HealthCare Pharmaceuticals Corporation, or Bayer, in its Q2 2011 Analyst
and Investor Briefing, announced net sales of Nexavar for the quarter ending June 30, 2011 of
171million. Quarterly, Nexavar sales are translated into U.S. dollars based on an average exchange
rate over the period. The approximate average exchange rate for the quarter ending June 30, 2011
was $1.44 for 1. Under the Collaboration Agreement between Bayer and Onyx, Bayer and Onyx share
profits from global Nexavar sales, except in Japan where Onyx receives a single digit royalty on
Nexavar net sales.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ONYX PHARMACEUTICALS, INC. |
||||
Dated: July 28, 2011 | By: | /s/ Matthew K. Fust | ||
Matthew K. Fust | ||||
Executive Vice President and Chief Financial Officer | ||||